[go: up one dir, main page]

NI201400112A - Tratamiento del cáncer con inhibidores tor cinasa - Google Patents

Tratamiento del cáncer con inhibidores tor cinasa

Info

Publication number
NI201400112A
NI201400112A NI201400112A NI201400112A NI201400112A NI 201400112 A NI201400112 A NI 201400112A NI 201400112 A NI201400112 A NI 201400112A NI 201400112 A NI201400112 A NI 201400112A NI 201400112 A NI201400112 A NI 201400112A
Authority
NI
Nicaragua
Prior art keywords
tor kinase
kinase inhibitors
cancer treatment
breast cancer
hormone receptor
Prior art date
Application number
NI201400112A
Other languages
English (en)
Inventor
Xu Shuichan
Mae Hege Kristen
Raymon Heather
K Narla Rama
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NI201400112A publication Critical patent/NI201400112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para tratar o prevenir cáncer de mama triple nagativo o cáncer de mama de receptores de hormonas positivos, que comprenden administrar una cantidad efectiva de un inhibidor de TOR cinasa a un paciente con cáncer de mama triple negativo o cáncer de mama de receptores de hormonas positivo.
NI201400112A 2012-03-15 2014-09-12 Tratamiento del cáncer con inhibidores tor cinasa NI201400112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611374P 2012-03-15 2012-03-15
US201261715331P 2012-10-18 2012-10-18

Publications (1)

Publication Number Publication Date
NI201400112A true NI201400112A (es) 2015-01-15

Family

ID=48014333

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400112A NI201400112A (es) 2012-03-15 2014-09-12 Tratamiento del cáncer con inhibidores tor cinasa

Country Status (19)

Country Link
US (2) US20130245027A1 (es)
EP (1) EP2825169B1 (es)
JP (2) JP2015511963A (es)
KR (1) KR102057359B1 (es)
CN (1) CN104271139A (es)
AU (1) AU2013202993B2 (es)
BR (1) BR112014022707A2 (es)
CA (1) CA2867348A1 (es)
ES (1) ES2678250T3 (es)
IL (1) IL234641B (es)
MX (1) MX360880B (es)
MY (1) MY178012A (es)
NI (1) NI201400112A (es)
NZ (1) NZ628407A (es)
PH (1) PH12014502046B1 (es)
SG (1) SG11201405724RA (es)
TW (1) TWI635862B (es)
WO (1) WO2013138553A1 (es)
ZA (1) ZA201406701B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105392499B (zh) * 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
CN113730412A (zh) 2013-04-17 2021-12-03 西格诺药品有限公司 用二氢吡嗪并-吡嗪治疗癌症
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
MX2015015880A (es) 2013-05-29 2016-05-31 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN112933088B (zh) * 2021-02-03 2022-02-22 南华大学附属第一医院 Y041-5921在制备抗肿瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2478635C2 (ru) * 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
KR101451290B1 (ko) 2006-10-19 2014-10-15 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
JP2011516580A (ja) * 2008-04-11 2011-05-26 バイオノボ・インコーポレーテッド トウサイカチｇｌｅｄｉｔｓｉａｓｉｎｅｎｓｉｓｌａｍの抽出物を用いる抗癌方法
EP2320894B1 (en) * 2008-08-20 2016-12-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN106117213B (zh) 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法

Also Published As

Publication number Publication date
TWI635862B (zh) 2018-09-21
BR112014022707A2 (pt) 2020-10-27
US20130245027A1 (en) 2013-09-19
SG11201405724RA (en) 2014-10-30
EP2825169B1 (en) 2018-05-09
JP2015511963A (ja) 2015-04-23
NZ628407A (en) 2016-04-29
ES2678250T3 (es) 2018-08-09
CN104271139A (zh) 2015-01-07
IL234641B (en) 2020-04-30
IL234641A0 (en) 2014-11-30
MY178012A (en) 2020-09-29
WO2013138553A1 (en) 2013-09-19
KR102057359B1 (ko) 2019-12-18
JP6470820B2 (ja) 2019-02-13
AU2013202993A1 (en) 2013-10-03
CA2867348A1 (en) 2013-09-19
MX360880B (es) 2018-11-21
US20230338370A1 (en) 2023-10-26
JP2018052963A (ja) 2018-04-05
PH12014502046A1 (en) 2014-12-10
AU2013202993B2 (en) 2015-09-03
KR20140138951A (ko) 2014-12-04
EP2825169A1 (en) 2015-01-21
ZA201406701B (en) 2016-05-25
TW201343165A (zh) 2013-11-01
PH12014502046B1 (en) 2020-10-16
HK1201753A1 (en) 2015-09-11
MX2014011118A (es) 2015-04-08

Similar Documents

Publication Publication Date Title
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2016005294A (es) Metodos para tratar y prevenir enfermedad injerto contra huésped.
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
MX380689B (es) Tratamiento de cancer con dihidropirazino-pirazinas.
MX2015014344A (es) Terapia contra el cancer.
BR112016024332A2 (pt) métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
MX2016002307A (es) Tratamiento para el cancer.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы
DOP2017000174A (es) Terapias de combinación para el tratamiento de cánceres
TH156277A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส